Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philip Scheltens

Showing results (611-620 of 903) with videos related to

Pageof 91
Sort By:
Clinical Chemistry|March 11, 2018
Neurogranin as Cerebrospinal Fluid Biomarker for Alzheimer Disease: An Assay Comparison StudyEline A J Willemse, Ann De Vos, Elizabeth M Herries, et al.
The Lancet. Neurology|June 16, 2009
Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort studyPieter Jelle Visser, Frans Verhey, Dirk L Knol, et al.
Cerebrovascular Diseases (Basel, Switzerland)|July 11, 2013
Deterioration of gait and balance over time: the effects of age-related white matter change--the LADIS studyStefan H Kreisel, Christian Blahak, Hansjörg Bäzner, et al.
Alzheimer'S Research & Therapy|July 20, 2019
Retinal thickness as potential biomarker in posterior cortical atrophy and typical Alzheimer's diseaseJurre den Haan, Lajos Csinscik, Tom Parker, et al.
The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences|February 9, 2017
Gait Speed and Grip Strength Reflect Cognitive Impairment and Are Modestly Related to Incident Cognitive Decline in Memory Clinic Patients With Subjective Cognitive Decline and Mild Cognitive Impairment: Findings From the 4C StudyAstrid M Hooghiemstra, Inez H G B Ramakers, Nicole Sistermans, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 12, 2014
The effect of amyloid pathology and glucose metabolism on cortical volume loss over time in Alzheimer's diseaseSofie M Adriaanse, Koene R A van Dijk, Rik Ossenkoppele, et al.
EJNMMI Research|August 17, 2018
A novel partial volume correction method for accurate quantification of [<sup>18</sup>F] flortaucipir in the hippocampusEmma E Wolters, Sandeep S V Golla, Tessa Timmers, et al.
Alzheimer Disease and Associated Disorders|March 18, 2014
Diagnostic criteria for vascular cognitive disorders: a VASCOG statementPerminder Sachdev, Raj Kalaria, John O'Brien, et al.
Alzheimer'S Research & Therapy|September 3, 2022
Longitudinal change in ATN biomarkers in cognitively normal individualsJarith L Ebenau, Denise Visser, Lior A Kroeze, et al.
The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences|August 15, 2019
Associations of Brain Pathology Cognitive and Physical Markers With Age in Cognitively Normal Individuals Aged 60-102 YearsNienke Legdeur, Betty M Tijms, Elles Konijnenberg, et al.
Pageof 91

Showing results (611-620 of 903) with videos related to

Sort By:
Pageof 91
Clinical Chemistry|March 11, 2018
Neurogranin as Cerebrospinal Fluid Biomarker for Alzheimer Disease: An Assay Comparison StudyEline A J Willemse, Ann De Vos, Elizabeth M Herries, et al.
The Lancet. Neurology|June 16, 2009
Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort studyPieter Jelle Visser, Frans Verhey, Dirk L Knol, et al.
Cerebrovascular Diseases (Basel, Switzerland)|July 11, 2013
Deterioration of gait and balance over time: the effects of age-related white matter change--the LADIS studyStefan H Kreisel, Christian Blahak, Hansjörg Bäzner, et al.
Alzheimer'S Research & Therapy|July 20, 2019
Retinal thickness as potential biomarker in posterior cortical atrophy and typical Alzheimer's diseaseJurre den Haan, Lajos Csinscik, Tom Parker, et al.
The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences|February 9, 2017
Gait Speed and Grip Strength Reflect Cognitive Impairment and Are Modestly Related to Incident Cognitive Decline in Memory Clinic Patients With Subjective Cognitive Decline and Mild Cognitive Impairment: Findings From the 4C StudyAstrid M Hooghiemstra, Inez H G B Ramakers, Nicole Sistermans, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 12, 2014
The effect of amyloid pathology and glucose metabolism on cortical volume loss over time in Alzheimer's diseaseSofie M Adriaanse, Koene R A van Dijk, Rik Ossenkoppele, et al.
EJNMMI Research|August 17, 2018
A novel partial volume correction method for accurate quantification of [<sup>18</sup>F] flortaucipir in the hippocampusEmma E Wolters, Sandeep S V Golla, Tessa Timmers, et al.
Alzheimer Disease and Associated Disorders|March 18, 2014
Diagnostic criteria for vascular cognitive disorders: a VASCOG statementPerminder Sachdev, Raj Kalaria, John O'Brien, et al.
Alzheimer'S Research & Therapy|September 3, 2022
Longitudinal change in ATN biomarkers in cognitively normal individualsJarith L Ebenau, Denise Visser, Lior A Kroeze, et al.
The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences|August 15, 2019
Associations of Brain Pathology Cognitive and Physical Markers With Age in Cognitively Normal Individuals Aged 60-102 YearsNienke Legdeur, Betty M Tijms, Elles Konijnenberg, et al.
Pageof 91